Lifecore Biomedical, Inc. (LFCR)
LFCR Stock Price Chart
Explore Lifecore Biomedical, Inc. interactive price chart. Choose custom timeframes to analyze LFCR price movements and trends.
LFCR Company Profile
Discover essential business fundamentals and corporate details for Lifecore Biomedical, Inc. (LFCR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
15 Feb 1996
Employees
382.00
Website
https://www.lifecore.comCEO
Paul Josephs
Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
LFCR Financial Timeline
Browse a chronological timeline of Lifecore Biomedical, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Oct 2026
EPS estimate is -$0.29, while revenue estimate is $25.96m.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.29, while revenue estimate is $33.13m.
Earnings released on 6 May 2026
EPS came in at -$0.43 falling short of the estimated -$0.24 by -79.17%, while revenue for the quarter reached $23.19m , missing expectations by -24.49%.
Earnings released on 6 Apr 2026
Earnings released on 16 Mar 2026
EPS came in at -$0.16 falling short of the estimated -$0.14 by -14.29%, while revenue for the quarter reached $35.15m , meeting expectations.
Earnings released on 6 Nov 2025
EPS came in at -$0.29 surpassing the estimated -$0.30 by +3.33%, while revenue for the quarter reached $31.11m , beating expectations by +18.47%.
Earnings released on 7 Aug 2025
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $36.44m , beating expectations by +3.02%.
Earnings released on 3 Apr 2025
EPS came in at -$0.19 falling short of the estimated -$0.14 by -35.71%, while revenue for the quarter reached $35.15m , beating expectations by +5.73%.
Earnings released on 2 Jan 2025
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $32.56m , beating expectations by +9.47%.
Earnings released on 4 Oct 2024
EPS came in at -$0.49 falling short of the estimated -$0.46 by -6.52%, while revenue for the quarter reached $24.71m , beating expectations by +6.54%.
Earnings released on 26 Aug 2024
EPS came in at -$0.15 falling short of the estimated -$0.12 by -25.00%, while revenue for the quarter reached $37.89m , beating expectations by +8.20%.
Earnings released on 21 Mar 2024
EPS came in at -$0.06 falling short of the estimated $0.07 by -185.71%, while revenue for the quarter reached $35.77m , meeting expectations.
Earnings released on 30 Nov 2023
EPS came in at -$0.33 falling short of the estimated -$0.23 by -43.48%, while revenue for the quarter reached $24.80m , beating expectations by +1.04%.
Earnings released on 31 Aug 2023
EPS came in at -$0.89 falling short of the estimated -$0.07 by -1.17k%, while revenue for the quarter reached $31.55m , beating expectations by +8.60%.
Earnings released on 1 Jun 2023
EPS came in at -$0.22 falling short of the estimated -$0.13 by -69.23%, while revenue for the quarter reached $27.60m , missing expectations by -1.42%.
Earnings released on 3 May 2023
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $25.52m , missing expectations by -8.85%.
Earnings released on 16 Mar 2023
EPS came in at -$0.24 falling short of the estimated -$0.21 by -14.29%, while revenue for the quarter reached $38.80m , missing expectations by -9.76%.
Earnings released on 6 Oct 2022
EPS came in at -$0.32 falling short of the estimated -$0.13 by -146.15%, while revenue for the quarter reached $43.36m , beating expectations by +1.44%.
Earnings released on 5 Apr 2022
EPS came in at -$0.08 falling short of the estimated $0.01 by -900.00%, while revenue for the quarter reached $53.07m , beating expectations by +9.63%.
Earnings released on 5 Jan 2022
EPS came in at $0.05 surpassing the estimated -$0.04 by +225.00%, while revenue for the quarter reached $129.49m , missing expectations by -1.66%.
Earnings released on 29 Sept 2021
EPS came in at -$0.23 falling short of the estimated -$0.12 by -91.67%, while revenue for the quarter reached $43.45m , beating expectations by +1.67%.
Earnings released on 28 Jul 2021
EPS came in at $0.07 surpassing the estimated -$0.01 by +800.00%, while revenue for the quarter reached $41.63m , missing expectations by -9.21%.
LFCR Stock Performance
Access detailed LFCR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
